ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1409

Ursolic Acid Promotes Apoptosis of Rheumatoid Athritis Synovial Fibroblasts By Upregulating Noxa Expression and Recruiting E3 Ligase Mule to Degrade Mcl-1

Eugene Kim1, Solomon Agere1, Sadik Khuder2 and Salahuddin Ahmed1, 1Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 2Department of Medicine, University of Toledo, Toledo, OH

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Apoptosis, Fibroblasts, rheumatoid arthritis (RA) and signal transduction

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: In our previous study, we discovered that ursolic acid (UA), a pentacyclic triterpenoid with anti-inflammatory properties, induces apoptosis in synovial fibroblasts from rheumatoid arthritis patients (RASFs) by upregulating Noxa and downregulating Mcl-1. To examine the molecular mechanism of UA-mediated apoptosis, we tested early signaling pathways that may activate Noxa expression as well as potential mechanisms of Noxa-mediated proteasomal degradation of Mcl-1 in human RASFs.

Methods: Human RASFs were treated with UA (5-10 μM) to determine the activated signaling pathways by Western blotting and qRT-PCR methods. The spatial association of Noxa with Mcl-1 and other E3 ligases was studied using immunoprecipitation (IP), immunofluorescence (IF), and proximal ligation assay (PLA) methods. The ubiquitination of Mcl-1 was studied using denatured IP.

Results: Treatment of RASFs with UA (5-10 μM) resulted in a time- and dose-dependent increase in Noxa, but decrease in Mcl-1 expression. Addition of proteasome inhibitor (MG132) showed no further increase in Noxa expression, suggesting transcriptional activation as a potential mechanism behind UA-induced Noxa expression. Evaluation of the signaling pathways showed that UA induced temporal expression of hypoxia-inducible factor-1 α (HIF-1α) in RASFs. Furthermore, our results showed that UA utilizes Akt, p38-MAPK, and JNK/SAPK signaling pathways to activate Noxa expression in RASFs. Utilizing inhibitors of JNK/SAPK (SP600125), p38-MAPK (SB203580), Akt (LY294002), and HIF-1a (HIF-1a inhibitor) pathways, we showed that inhibition of JNK/SAPK pathway significantly reduced UA-mediated upregulation of Noxa. In addition, the results from PLA and IF studies in UA-treated RASFs showed that Noxa co-localizes with Mcl-1 predominantly in the non-nuclear compartment of the cell, suggesting its association with Mcl-1 in ‘priming’ Mcl-1 for proteasomal degradation. Interestingly, the IP of Mcl-1 under denatured condition after UA treatment and subsequent Western blot analysis showed an increase in K48-linked, but not K63-linked, ubiquitin chains tagged to Mcl-1. This K48 polyubiquitylation of Mcl-1 appears to be mediated by Mule, a HECT domain containing E3 ubiquitin-protein ligase, since UA treatment of RASFs preferentially induced the recruitment of Mule rather than SCFβ-TrCP to Noxa/Mcl-1 complex to facilitate Mcl-1 degradation.

Conclusion: Taken together, these results suggest that UA induces Noxa expression via JNK pathway and facilitates Mcl-1 association with E3 ubiquitin ligase Mule to activate Mcl-1 degradation that sensitizes RASFs to apoptosis. These findings not only unveil a novel mechanism of UA in inducing apoptosis of RAFSs, but also a potential new approach to treat RA.


Disclosure: E. Kim, None; S. Agere, None; S. Khuder, None; S. Ahmed, None.

To cite this abstract in AMA style:

Kim E, Agere S, Khuder S, Ahmed S. Ursolic Acid Promotes Apoptosis of Rheumatoid Athritis Synovial Fibroblasts By Upregulating Noxa Expression and Recruiting E3 Ligase Mule to Degrade Mcl-1 [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/ursolic-acid-promotes-apoptosis-of-rheumatoid-athritis-synovial-fibroblasts-by-upregulating-noxa-expression-and-recruiting-e3-ligase-mule-to-degrade-mcl-1/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ursolic-acid-promotes-apoptosis-of-rheumatoid-athritis-synovial-fibroblasts-by-upregulating-noxa-expression-and-recruiting-e3-ligase-mule-to-degrade-mcl-1/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology